+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Dermal Allograft Innovation Grants

MTF Biologics

MTF Biologics is pleased to announce the opening of the 2026 Dermal Allografts Innovations Research Grants, a new funding opportunity focused on advancing next-generation of technologies in allograft dermis and skin.

Allograft dermal matrices (ADMs) and skin allografts are widely used in reconstructive and regenerative procedures, including breast surgery, wound healing, and abdominal wall reconstruction. Current applications primarily rely on sheet-based products. However, there is an increasing need for innovative technologies that expand the versatility of ADM and skin, increase clinical utility, improve storage and handling, and enable new clinical applications. Emerging concepts such as flowable or particulate ADM, 3D-printed constructs, tissue-engineered skin, viable dermal tissues, and advanced preservation technologies represent transformative opportunities for patient care.

MTF Biologics invites Translational Research proposals that accelerate innovation in allograft dermis and skin by developing new enabling technologies, novel clinical uses, advanced processing or delivery methods, and next-generation product forms.

Program Objectives

The Dermal Allograft Innovations Grant aims to support research that will:

• Drive technological breakthroughs in allograft dermis and skin beyond traditional sheet-based formats.

• Develop new tissue products (e.g., flowable ADM, ground or particulate ADM, viable dermal tissue constructs) to improve adaptability and efficacy in complex surgical scenarios.

• Explore integration with advanced platforms, including 3D bioprinting and tissue engineering approaches for skin regeneration.

• Innovate processing and preservation technologies, such as room-temperature storage solutions for burn-care grafts that reduce the need for cryopreservation.

• Advance ADM applications in existing clinical indications through novel designs and transformative product concepts.

Funding

• Funding available: Up to $100,000 for a 12-month project period.

• Up to two additional 12-month cycles of continued funding may be awarded based on progress, milestones achieved, and programmatic impact.

Letters of Intent (LOI) Due Date - March 23, 2026

Announcement of LOI positive review and Request for full proposal – by end of April 2026

Full Proposal Due Date (if LOI is approved) - June 15, 2026

Announcement of Awards to Grant Recipients – by end of October 2026

AI Based Application Success Predictor

🧬 1. Strict Focus on Allograft Tissue Science (Non-Negotiable)

Projects must directly involve:
- Allografts or allograft-derived materials
Core domains:
- Tissue transplantation
- Regenerative medicine
- Biologic reconstruction

👉 Projects without a clear allograft component are out of scope

🔄 2. Strong Translational Pathway (Top Predictor)

MTF explicitly prioritizes:
- Translational and clinical research
Must show:
- Clear path from:
  - Lab → clinical application

👉 Key question:
“How will this improve patient outcomes using allograft technologies?”

Proposals lacking translation are often not funded

🎯 3. Clear Clinical Impact (Critical)

Successful proposals:

Demonstrate:
- Improvement in surgical or clinical outcomes
Relevant areas:
- Orthopaedics
- Plastic/reconstructive surgery
- Wound care

👉 Clinical relevance must be explicit in aims and design

🚀 4. Innovation in Allograft Technologies

High success areas include:

New uses of allografts
Advanced processing or preservation
Novel delivery systems
3D-printed or engineered tissues

👉 Innovation must be practical and clinically applicable

🧪 5. Feasible, Milestone-Driven Study Design

Grants are:
- Project-based and outcome-driven
Must include:
- Clear aims
- Achievable milestones

👉 Overly theoretical or vague proposals are commonly rejected

🧠 6. Use of Advanced Technologies (Competitive Advantage)

Strong preference for:
- Integration of:
  - AI / precision medicine
  - Biomaterials
  - Tissue engineering

👉 Modern, tech-integrated approaches score higher

👩‍🔬 7. Investigator Strength & Career Stage Fit

Programs support:
- Junior investigators
- Established researchers
Evaluation includes:
- Track record
- Ability to execute translational research

👉 Dedicated tracks exist for different career levels

🤝 8. Multidisciplinary & Surgical Collaboration

Strong proposals often include:
- Surgeons + scientists + engineers
Especially important in:
- Orthopaedics and reconstructive fields

👉 Collaboration improves feasibility and clinical relevance

🌍 9. Addressing Unmet Clinical Needs

Priority given to:
- Problems in:
  - Tissue repair
  - Reconstruction
  - Wound healing

👉 Projects solving real clinical gaps are favored

📈 10. Potential for Future Funding & Clinical Adoption

MTF funding acts as:
- Seed funding
Strong proposals:
- Lead to:
  - Larger grants (NIH, DoD, etc.)
  - Clinical implementation

👉 Scalability and future impact matter

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Allograft-specific focus
Translational pathway
Clinical impact

Moderate predictors:
4. Innovation
5. Feasibility
6. Technology integration

Supporting factors:
7. Investigator strength
8. Collaboration
9. Future funding potential

💡 Insider Insight

Compared to general biomedical funders:

MTF Biologics is:
👉 highly niche (allograft science only)
👉 strongly translation- and surgery-driven

👉 Winning formula:
Allograft-based innovation + clear clinical application + feasible translational study

Specialties

Clinical Trials

Eligibility Requirements

Eligible applicants include investigators with expertise in tissue engineering, regenerative medicine, biomaterials science, plastic and reconstructive surgery, or related fields, who hold an appointment at an academic institution, teaching hospital, or research organization.

Sponsor Details

Sponsor Institute/Organizations: MTF Biologics

Sponsor Type: Corporate/Non-Profit

Address: 125 May Street Edison, NJ 08837 732-661-0202 800-946-9008 www.mtfbiologics.org

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity